KR20000071039A - 비타민 ｄ 화합물의 표적화된 치료학적 전달 - Google Patents

비타민 ｄ 화합물의 표적화된 치료학적 전달 Download PDF

Info

Publication number
KR20000071039A
KR20000071039A KR1019997007306A KR19997007306A KR20000071039A KR 20000071039 A KR20000071039 A KR 20000071039A KR 1019997007306 A KR1019997007306 A KR 1019997007306A KR 19997007306 A KR19997007306 A KR 19997007306A KR 20000071039 A KR20000071039 A KR 20000071039A
Authority
KR
South Korea
Prior art keywords
conjugate
vitamin
residue
bone
target molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019997007306A
Other languages
English (en)
Korean (ko)
Inventor
마제스리차드비
비숍찰스더블유
Original Assignee
비숍 찰스 더블유.
본 케어 인터내셔널, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비숍 찰스 더블유., 본 케어 인터내셔널, 인코포레이티드 filed Critical 비숍 찰스 더블유.
Publication of KR20000071039A publication Critical patent/KR20000071039A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1019997007306A 1997-02-13 1998-02-13 비타민 ｄ 화합물의 표적화된 치료학적 전달 Withdrawn KR20000071039A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3836497P 1997-02-13 1997-02-13
US60/038,364 1997-02-13

Publications (1)

Publication Number Publication Date
KR20000071039A true KR20000071039A (ko) 2000-11-25

Family

ID=21899512

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997007306A Withdrawn KR20000071039A (ko) 1997-02-13 1998-02-13 비타민 ｄ 화합물의 표적화된 치료학적 전달

Country Status (12)

Country Link
US (1) US6929797B2 (https=)
EP (1) EP0981376A1 (https=)
JP (1) JP2001511811A (https=)
KR (1) KR20000071039A (https=)
CN (1) CN1254293A (https=)
AU (1) AU750451B2 (https=)
BR (1) BR9815442A (https=)
CA (1) CA2279590A1 (https=)
HU (1) HUP0002454A2 (https=)
NZ (1) NZ336924A (https=)
PL (1) PL336231A1 (https=)
WO (1) WO1998035704A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150009997A (ko) * 2012-05-17 2015-01-27 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531459B1 (en) 1997-12-17 2003-03-11 Schering Aktiengesellschaft Vitamin D derivatives with phosphorus atoms in the side chains
US7598246B2 (en) 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
US6518302B1 (en) 1999-01-20 2003-02-11 Takara Shuzo Co., Ltd. Remedies
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
WO2002083150A1 (en) * 2001-04-10 2002-10-24 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
DE10156596A1 (de) * 2001-11-13 2003-05-28 Schering Ag Vitamin D-Derivate mit Acyloxygruppen in der Seitenkette, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
JP5161582B2 (ja) * 2004-11-22 2013-03-13 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
WO2006096555A1 (en) * 2005-03-04 2006-09-14 Women And Infants Hospital Of Ri, Inc. Compositions and methods for cancer treatment
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
CA2646909A1 (en) * 2006-04-06 2008-03-27 Hector F. Deluca 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
US7648973B2 (en) * 2006-04-06 2010-01-19 Wisconsin Alumni Research Foundation 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
CA2710954C (en) * 2007-12-28 2015-07-21 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
US7718638B2 (en) * 2007-12-28 2010-05-18 Wisconsin Alumni Research Foundation (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
EP2289558A1 (en) * 2009-08-25 2011-03-02 KTB Tumorforschungsgesellschaft mbH Bisphosphonate-prodrugs
WO2011045668A1 (en) * 2009-10-14 2011-04-21 The Governors Of The University Of Alberta Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof
EP2515913A2 (en) * 2009-12-23 2012-10-31 Glycomyr Inc. Use of vitamin d glycosides and sulfates for treatment of disease
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
WO2013019874A1 (en) * 2011-08-01 2013-02-07 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
US9244083B2 (en) 2012-11-30 2016-01-26 Siemens Healthcare Diagnostics Inc. Compositions and methods for detecting vitamin D
US9618523B2 (en) 2013-02-28 2017-04-11 Siemens Healthcare Diagnostics Inc. Methods and reagents for determining isomeric analytes
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CN105381470B (zh) * 2015-11-27 2018-11-02 广东医科大学 一种改性染料木素及其应用
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
CN111440105B (zh) * 2020-04-01 2022-05-17 南通华山药业有限公司 阿法骨化醇氨基甲酸酯衍生物及其制备方法和用途
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
CN116082536B (zh) * 2023-02-16 2024-04-26 广州汇元医药科技有限公司 具有骨靶向功能的聚合物及其制备方法和用途、纳米载体及其制备方法
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2383446A (en) * 1941-06-04 1945-08-28 Du Pont Antirachitic materials and processes for their production
US3697559A (en) * 1971-02-25 1972-10-10 Wisconsin Alumni Res Found 1,25-dihydroxycholecalciferol
US3741996A (en) * 1971-12-02 1973-06-26 Wisconsin Alumni Res Found 1{60 -hydroxycholecalciferol
US3907843A (en) * 1974-06-14 1975-09-23 Wisconsin Alumni Res Found 1{60 -Hydroxyergocalciferol and processes for preparing same
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
NL188286C (nl) 1978-01-16 1992-05-18 Wisconsin Alumni Res Found Werkwijze voor het bereiden van een 1alfa-hydroxyvitamine d verbinding.
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4160803A (en) * 1978-03-23 1979-07-10 Corning Glass Works Self packaged test kit
US4225596A (en) 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4292250A (en) * 1980-11-17 1981-09-29 Wisconsin Alumni Research Foundation Vitamin D derivatives
JPS57149224A (en) 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4508651A (en) * 1983-03-21 1985-04-02 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
CH665834A5 (de) 1983-05-09 1988-06-15 Wisconsin Alumni Res Found Verfahren zur herstellung von 1alpha,25-dihydroxyliertem vitamin d(2) und verwandten verbindungen.
US4689180A (en) * 1984-01-30 1987-08-25 Wisconsin Alumni Research Foundation 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4717721A (en) * 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4661294A (en) * 1985-03-18 1987-04-28 The General Hospital Corporation Biologically active 1-thio derivatives of vitamin D
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
GR861167B (en) 1985-05-02 1986-09-30 Research Corp Bone targeted inhibitors of carbonic anhydrase
JPH07100685B2 (ja) 1985-08-02 1995-11-01 レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ／エス（レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ） 新規ビタミンｄ類似体
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US5338532A (en) * 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4902481A (en) * 1987-12-11 1990-02-20 Millipore Corporation Multi-well filtration test apparatus
US5232836A (en) * 1988-05-04 1993-08-03 Ire-Medgenix S.A. Vitamin D derivatives: therapeutic applications and applications to assays of metabolites of vitamin D
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
JPH0778024B2 (ja) 1988-10-14 1995-08-23 藤沢薬品工業株式会社 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
JP2645130B2 (ja) * 1989-03-31 1997-08-25 日清製粉株式会社 ステロイド誘導体
US5063221A (en) * 1989-04-05 1991-11-05 Chugai Seiyaku Kabushiki Kaisha Treatment for hyperparathyroidism with use of vitamin d derivatives
US5219528A (en) * 1989-07-28 1993-06-15 Pierce Chemical Company Apparatus for rapid immunoassays
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5141719A (en) * 1990-07-18 1992-08-25 Bio-Rad Laboratories, Inc. Multi-sample filtration plate assembly
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
EP0503035B1 (en) 1990-09-21 2001-12-12 Bone Care International, Inc. Novel 1alpha-hydroxy vitamin d4 and novel intermediates and analogues
AU1247592A (en) 1991-01-08 1992-08-17 Lunar Corporation Methods for preparation and use of 1alpha,24-dihydroxy vitamin d2
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
WO1992014493A1 (en) * 1991-02-20 1992-09-03 Christopher Capelli Non-protein intracellular receptor binding conjugates and a method of use thereof
DK0503630T3 (da) 1991-03-13 1996-01-29 Kuraray Co Cyclohexantriolderivater
US5264184A (en) * 1991-03-19 1993-11-23 Minnesota Mining And Manufacturing Company Device and a method for separating liquid samples
US5417923A (en) * 1991-04-24 1995-05-23 Pfizer Inc. Assay tray assembly
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
KR100244603B1 (ko) * 1991-05-28 2000-03-02 데이비드 엠 모이어 칼슘,미량무기물,비타민 디 또는 디포스포네이트를 포함하는 골 강화용 식품 보충제
ATE143007T1 (de) * 1991-07-05 1996-10-15 Duphar Int Res Vitamin-d derivat, verfahren zu dessen herstellung sowie zwischenprodukte dafür
US5205989A (en) * 1991-09-18 1993-04-27 Minnesota Mining And Manufacturing Company Multi-well filtration apparatus
DE69233046T2 (de) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
CA2129120A1 (en) 1992-01-29 1993-08-05 Bone Care International, Inc. 1.alpha.-hydroxy-24-epi-vitamin d4
EP0562497A1 (en) 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions
JPH05320127A (ja) 1992-03-27 1993-12-03 Nisshin Flour Milling Co Ltd 活性型ビタミンｄ誘導体
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
JP2520074B2 (ja) * 1992-06-11 1996-07-31 呉羽化学工業株式会社 新規なエストラジオ―ル誘導体−クロラムブチル結合体、その製造方法、及び医薬製剤
JP3722832B2 (ja) * 1992-06-22 2005-11-30 ルーナー、コーポレーション 経口用１α−ヒドロキシプレビタミンＤ
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5350745A (en) 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
DE69503394T2 (de) 1994-01-20 1999-03-11 Duphar International Research B.V., Weesp Vitamin-D-Derivate und Verfahren zu deren Herstellung
US5597575A (en) * 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US5739271A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5691328A (en) * 1996-02-02 1997-11-25 Clarion Pharmaceuticals Inc. Phosphoethanolamine conjugates of vitamin D compounds
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150009997A (ko) * 2012-05-17 2015-01-27 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어

Also Published As

Publication number Publication date
US20020136731A1 (en) 2002-09-26
CN1254293A (zh) 2000-05-24
NZ336924A (en) 2001-06-29
AU6326798A (en) 1998-09-08
BR9815442A (pt) 2001-08-21
CA2279590A1 (en) 1998-08-20
EP0981376A1 (en) 2000-03-01
JP2001511811A (ja) 2001-08-14
PL336231A1 (en) 2000-06-19
US6929797B2 (en) 2005-08-16
AU750451B2 (en) 2002-07-18
HUP0002454A2 (hu) 2000-12-28
WO1998035704A1 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
KR20000071039A (ko) 비타민 ｄ 화합물의 표적화된 치료학적 전달
US20030129194A1 (en) Targeted therapeutic delivery of vitamin D compounds
US5972917A (en) 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
EP1080055B1 (en) 24-hydroxyvitamin d, analogs and uses thereof
JP3865411B2 (ja) 抗−エンドトキシン化合物
EP0511917B1 (fr) Prodrogues glycosylées, leur procédé de préparation et leurs utilisations
US4661294A (en) Biologically active 1-thio derivatives of vitamin D
KR20000062405A (ko) 지연방출성 및/또는 서방출성 비타민 ｄ 제형을 사용하여 전립선 질환을 치료하는 방법
FI97692C (fi) Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi
WO2003002060A2 (en) Method of treating malignancy associated hypercalcemia using active vitamin d analogues
Rogers et al. Plasma clearance of an antibody-enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo
Dubowchik et al. Improved cytotoxicity of antitumor compounds deliverable by the LDL pathway
MXPA99007334A (en) Targeted therapeutic delivery of vitamin d compounds
CZ287499A3 (cs) Cílené dodání sloučenin vitaminu D
RU2719486C2 (ru) Гликолипидные соединения и их применение в лечении опухолей
CA1219581A (en) Vitamin d glycosides and a method for use
CN116806157A (zh) 接头-有效载荷及其缀合物
MXPA00011215A (en) 1&agr;-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF
JPH0813744B2 (ja) ９，１０−セコ−５，７，１０（１９）−プレグナトリエン誘導体を有効成分とする医薬
AU2002318421A1 (en) Method of treating malignancy associated hypercalcemia using active vitamin D analogues

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990812

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid